Special Scientific Symposia
The Special Scientific Symposia feature presentations that cover the latest scientific developments that cut across many sub-disciplines of hematology and appeal to a wide audience.
Unless otherwise noted, all sessions will take place in person and stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform.
Cellular Heterogeneity and Relationship to Clinical Outcomes
Sunday, December聽8,聽2024,聽4:30聽p.m.聽-聽5:45聽p.m.
San Diego Convention Center, Room 33
Cellular therapies are by nature heterogeneous, but regulatory and industry groups have focused on defining products with "critical product attributes" while minimizing heterogeneity or discounting the challenges of obtaining homogenous populations of cells. Understanding the potential risks and benefits of cellular heterogeneity, in both post-transplant and immune effector cell populations, is important information for cell therapy practitioners and researchers alike. In this session, we will hear from speakers with expertise in studying both natural and purposefully designed heterogeneous cellular products and will consider the benefits and technical challenges of obtaining purely homogenous populations of cells.
Dr. Good will present research on factors correlating with response and toxicity outcomes in chimeric antigen receptor (CAR) T cell treatment of large B cell lymphoma (LBCL). In particular, she will discuss the heterogeneity of CAR T cells, focusing on the impact of CAR T regulatory cells (Treg) on efficacy and neurotoxicity. Additionally, Dr. Good will share unpublished findings on T cell intrinsic factors affecting CAR T cell expansion, persistence, and tumor homing, results obtained from lineage tracing studies using endogenous T cell receptor sequences.
As screening tools have improved, we are now able to simultaneously query the entire genome to rapidly pinpoint key genetic nodes that govern human T cell behaviors. Dr. Carnevale will share studies using these screening tools to pressure test T cell therapies and identify loss- and gain-of-function gene targets that can be used to steer T cells into desired therapeutic behaviors. Specifically, she will cover lessons learned and steps being taken to successfully harness pooled screening approaches in T cells. She will also describe how these efforts might be translated to a clinical future where engineered pools of T cell products are created based on a variety of unique gene edits in CD4 and CD8 T cells.
Treg maintain immune homeostasis and are a promising cell therapy to induce transplantation tolerance. Dr. Levings will discuss the challenges to the wider applicability of Treg therapy, including a difficulty in obtaining large numbers of homogeneous cells and the technical ability to maximize the potency of the finalized product. In particular, work towards the scale up and clinical testing of an allogeneic 鈥渙ff the shelf鈥 Treg product, as well as the use of chimeric antigen receptor engineering to maximize Treg potency and tolerance induction, will be discussed.
Chair:
颁谤补颈驳听叠测别谤蝉诲辞谤蹿别谤,听惭顿
University of Pittsburgh
笔颈迟迟蝉产耻谤驳丑,听笔础
Speakers:
窜颈苍补颈诲补听骋辞辞诲,听笔丑顿
Stanford University School of Medicine
厂迟补苍蹿辞谤诲,听颁础
Heterogeneity of CD19 CAR T Cells
闯耻濒颈补听颁补谤苍别惫补濒别,听惭顿
University of California San Francisco
San Francisco,聽CA
Purposeful Heterogeneity of CAR T Cells
惭别驳补苍听尝别惫颈苍驳蝉
University of British Columbia, Canada
痴补苍肠辞耻惫别谤,听叠颁,听颁础狈
Heterogeneity of Cells in Transplantation
Interface of Complement and Coagulation
Saturday, December聽7,聽2024,聽4:00聽p.m.聽-聽5:15聽p.m.
San Diego Convention Center, Room 33
The complement system and coagulation pathways are the main pillars of immunity and hemostasis respectively that undergo significant activation with injury. While appearing distinct, it is recognized that significant crosstalk exists between the two systems and recently established molecular mechanisms provide insights into a wide variety of disorders. This session will focus on new molecular links identified in complement activation in specific and highly relevant clinical disorders.
Chair:
顿补惫颈诲听碍补惫补苍补驳丑
New Castle University
Newcastle Upon Tyne,聽United Kingdom
Speakers:
顿补惫颈诲听碍补惫补苍补驳丑
New Castle University
Newcastle Upon Tyne,聽United Kingdom
Complement and the Prothrombotic State
Efthymia聽Vlachaki,聽Consultant Hematologist
Hippokrateon Hospital
罢丑别蝉蝉补濒辞苍颈办颈,听骋谤别别肠别
Complement Activation and Preclampsia
Lubka T聽Roumenina,聽PhD
INSERM UMRS1138 Cordeliers Research Center
笔补谤颈蝉,听贵谤补苍肠别
Sickle Cell Disease and Complement Activation
Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies
Sunday, December聽8,聽2024,聽9:30聽a.m.聽-聽10:45聽a.m.
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13
Alterations in the intestinal microbiome are linked to responses and outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) and chimeric antigen receptor (CAR) T-cell therapy. This session will highlight emerging research investigating the host-microbiome axis in this context. We will assess factors that alter the intestinal microbiome in recipients of these cellular therapies, including diet and antibiotic exposure. Further, we will evaluate interventions to modulate the microbiome in this setting, namely fecal microbiota transplant.
Dr. Malard will discuss the role of fecal microbiota transplant in hematological malignancies, focusing on allo-HCT. He will provide an overview of the available clinical data on fecal microbiota transplant for treating graft-versus-host disease after allo-HCT. Dr. Malard will also discuss the potential of this procedure to prevent graft-versus-host disease and mitigate infection. He will also address the role of fecal microbiota transplant as a strategy to eradicate multidrug-resistant bacteria in patients who have undergone allo-HCT. Finally, the potential mechanism of action of fecal microbiota transplant and the implications of fecal microbiota transplant for CAR-T will be discussed.
Dr. David will share an approach for using metagenomic sequencing of fecal samples to track dietary intake in recipients of allo-HCT. He will illustrate how this method, FoodSeq, was initially tested using hospital-based foods. Dr. David will also show how FoodSeq was applied to a patient population, revealing reductions in food intake after allo-HCT. Notably, he will also demonstrate how these changes in food intake were linked to aspects of patient outcomes and microbiome changes following allo-HCT.
Dr. Andermann will explore how antibiotics influence the gut microbiome, the antimicrobial resistome (the collection of resistance genes in the gut), and immunologic/infectious outcomes in patients undergoing allo-HCT and CAR-T. She will review previous research findings and describe how anaerobically active antibiotics alter taxonomic and resistance gene composition in the gut during allo-HCT. Additionally, she will compare the spectrum of activity of antibiotics commonly used for febrile neutropenia, emphasizing the need for further research on how these antibiotics distribute throughout the gut lumen and drive changes in the abundance of commensal gut bacteria in recipients of cellular therapy.
Chair:
惭别濒辞诲测听厂尘颈迟丑,听惭顿,惭厂
Stanford University School of Medicine
厂迟补苍蹿辞谤诲,听颁础
Speakers:
Florent聽Malard,聽M.D., Ph.D.
Sorbonne Universit茅, H么pital Saint-Antoine, AP-HP, Service d'H茅matologie Clinique et Th茅rapie Cellulaire,Centre de Recherche Saint-Antoine UMRs938
笔补谤颈蝉,听贵谤补苍肠别
Fecal Microbiota Transplant As a Strategy to Mitigate Infection and Gvhd Following TCT
Lawrence A聽David,聽PhD
Duke University
顿耻谤丑补尘,听狈颁
Deciphering Nutritional Intake from Metagenomic Data Using Computational Tools
罢别蝉蝉补听础苍诲别谤尘补苍苍,听惭顿,惭笔贬
University of North Carolina, Chapel Hill
Chapel Hill,聽NC
Impact of Antibiotic Exposure on Outcomes Following TCT
Newly Discovered Functions of Megakaryocytes and Platelets
Sunday, December聽8,聽2024,聽4:30聽p.m.聽-聽5:45聽p.m.
San Diego Convention Center, Room 29
This session will explore cutting-edge discoveries in platelet biogenesis and the pathological mechanisms underlying platelet-related disorders.
Key topics include the role of glycosylation in megakaryocyte (Mk) and platelet (PLT) functions and their involvement in disease. Focus will be placed on the role of sialic acid and galactose modifications in regulating megakaryocyte-primed hematopoietic stem cell function and megakaryocyte activity, especially in relation to thrombocytopenia, including immune thrombocytopenias. Additionally, novel insights into thrombo-inflammation will be discussed, highlighting how inflammatory processes contribute to thrombosis and platelet dysfunction. Emerging research on the role of megakaryocytes and platelets in bone marrow fibrosis will also be featured, shedding light on their dual function in both hematopoiesis and pathological fibrosis. These topics are highly relevant, particularly with ongoing advancements in understanding the basic mechanisms of platelet production, glycosylation, and the interaction between thrombosis and inflammation.
Dr. Karin Hoffmeister will discuss the role of sialic acid and galactose modifications in regulating megakaryocyte activity. These glycan decorations are crucial for maintaining proper megakaryocyte function and platelet production, with disruptions contributing to platelet clearance and immune-mediated destruction in conditions like immune thrombocytopenia (ITP).
Dr. Tobias Petzold will discuss novel insights on natural occurring resilience mechanism to prevent thromboinflammation as key pathomechanism in thrombotic diseases. By introducing the concept of long-term immobility induced thromboprotection we will learn from a novel animal model- the hibernating brown bear - that is protected from developing venous thrombosis during 6 months of immobility in winter.聽 These findings will be translated into the clinical context.
Dr. Anna Nam will discuss the impact of ER stress and the unfolded protein response on megakaryopoiesis and platelets due to mutations in CALR in essential thrombocythemia and myelofibrosis. Using advanced single-cell multi-omics approaches, we show that CALR mutations elicit the unfolded protein response in human. Targeting ER stress-related pathways leads to reduction in platelet burden in mouse models.
Chair:
础濒别蝉蝉补苍诲谤补听叠补濒诲耻颈苍颈,听惭顿
Tufts University
惭别诲蹿辞谤诲,听惭础
Speakers:
Karin M.聽Hoffmeister,聽MD
Versiti Blood Research Institute, Milwaukee, WI
惭颈濒飞补耻办别别,听奥滨
Unveiling the Sweet Side of Platelet Formation: Exploring the Pivotal Role of Glycans
罢辞产颈补蝉听笔别迟锄辞濒诲,听惭顿,惭厂肠
Charit茅 鈥 Universit盲tsmedizin Berlin
叠别谤濒颈苍,听骋别谤尘补苍测
Regulation of Platelet Function During Immobilty
Anna S.聽Nam,聽MD
Weill Cornell Medicine
New York,聽NY
ER Stress in Megakaryopoiesis
Placing the Brakes on Accelerated Aging
Monday, December聽9,聽2024,聽4:30聽p.m.聽-聽5:45聽p.m.
San Diego Convention Center, Room 30
Hematologic disorders disproportionately affect older adults; despite this, our understanding of the implications of age on the pathogenesis and treatment of these diseases remains limited. The geroscience field is actively investigating geriomics to aid in distinguishing biological and chronological aging. This session will highlight biological aging assessments for hematologic disease which will be crucial for the identification of targets and development of therapies for this specific population.
Chair:
础蝉丑濒别测听搁辞蝉办辞,听惭顿
The Ohio State University
颁辞濒耻尘产耻蝉,听翱贬
Speakers:
贰濒蝉听惭补苍蝉别濒濒,听笔丑顿
Erasmus Medical Center
搁辞迟迟别谤诲补尘,听狈别迟丑别谤濒补苍诲蝉
Aging of Hematopoietic Stem Cells and Their Niche
Christin E聽Burd,聽PhD
Ohio State
颁辞濒耻尘产耻蝉,听翱贬
Geroscience and Geri-Omics in Hematologic Malignancies
Marcel R.M.聽van den Brink,聽MD, PhD
City of Hope National Medical Center
顿耻补谤迟别,听颁础
Targeting Rejuvenation Therapies to Decelerate Aging
Special Symposium on the Basic Science of Hemostasis and Thrombosis
Monday, December聽9,聽2024,聽4:30聽p.m.聽-聽6:00聽p.m.
San Diego Convention Center, Room 31
This session will highlight emerging topics and the latest discoveries in regulating inflammation at the cross-section of hemostasis, platelets, and vascular biology.
Co-Chairs:
Laurent O.聽Mosnier,聽PhD
The Scripps Research Inst.
La Jolla,聽CA
贬补谤迟尘耻迟听奥别颈濒别谤,听笔丑顿
Versiti Blood Research Institute
惭颈濒飞补耻办别别,听奥滨
Lijun聽Xia,聽MD, PhD
Oklahoma Medical Research Foundation
Oklahoma City,聽OK
Speakers:
Yesim聽Dargaud,聽MD, PhD
Hopital Edouard Herriot Pav. E
尝测辞苍,听贵谤补苍肠别
Role of Extravascular FIX in Hemophilia
闯颈别辩颈苍驳听窜丑耻,听笔丑顿
Versiti Blood Research Institute
惭颈濒飞补耻办别别,听奥滨
Platelet Integrin Structure, Function and Role in Disease
驰耻听贬辞耻,听笔丑顿
Qilu Hospital, Cheeloo College of Medicine, Shandong University
闯颈苍补苍,听颁贬狈
Platelet TGFb1 in the Pathogenesis of Immune Thrombocytopenia Purpura
Amelia K聽Haj,聽MD,PhD
Massachusetts General Hospital
颁补尘产谤颈诲驳别,听惭础
Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism
66th ASH Annual Meeting and exposition
Registration for ASH members, non-members, groups, exhibitors, and media is now open!